1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
Kasumi-3 represents a lymphoblast cell line established in 1990, originating from a 57-year-old male of Asian descent diagnosed with acute myeloblastic leukemia. These cells exhibit a notable t(3;7) chromosomal translocation, leading to the alteration of MECOM-TRB (EVI1-TRB) genes and subsequent overexpression of MECOM (EVI1). They are characterized by surface expression of CD7, CD4, CD13, CD33, CD34, HLA-DR, and c-Kit. Additionally, Kasumi-3 cells display other chromosomal abnormalities, including del(5)(q15), del(9)(q32), and add(12)(p11). Upon exposure to TPA, these cells demonstrate a maturation shift toward the monocytic lineage. Notably, their proliferation is induced by treatment with interleukins (IL-2, IL-3, IL-4), granulocyte-macrophage colony-stimulating factor, and stem cell factor.
Why choose Kasumi-3 from AcceGen?
Kasumi-3 cells from AcceGen are characterized by their exceptional quality and high viability. They have been meticulously cultured under optimal conditions, ensuring their reliability for research purposes. These cells are provided in a sterile state, thoroughly screened for the absence of bacteria and fungi, and confirmed mycoplasma-free through PCR assays. Their identity has also been authenticated using STR analysis, further ensuring their integrity and suitability for scientific investigations.
| Product Code | KASUMI-3; KASUMI3; Kasumi3 |
| Species | Human |
| Cat.No | ABL-TC0325 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Blood |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
Kasumi-3 cells have proven invaluable in various research domains, particularly within the context of acute myeloblastic leukemia (AML) and immune system disorder investigations. In the realm of AML research, they serve as a vital tool for the study of the M0 subtype, offering insights into the disease’s biological characteristics. Furthermore, these cells are instrumental in unraveling the role of the EVI1 gene in leukemogenesis. Moreover, their applicability extends to the emerging field of 3D cell culture, providing a versatile platform for simulating complex tissue environments and enabling the exploration of novel therapeutic strategies in AML and immunology research.
